A nano-cocktail of the PARP inhibitor talazoparib and CDK inhibitor dinaciclib for the treatment of triple negative breast cancer
Abstract Background The addition of the cyclin dependent kinase inhibitor (CDKi) dinaciclib to Poly-(ADP-ribose) polymerase inhibitor (PARPi) therapy is a strategy to overcome resistance to PARPi in tumors that exhibit homologous recombination (HR) deficiencies as well as to expand PARPi therapy to...
Guardat en:
| Autors principals: | , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMC
2024-03-01
|
| Col·lecció: | Cancer Nanotechnology |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1186/s12645-023-00240-4 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|